Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th
GERMANTOWN, Md., Aug. 3, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON) today announced it will release first half and second quarter 2015 financial results after the market closes on Monday, August 10th, 2015.  The Company will host a conference call at 5:30 PM ET to discuss the results and provide a general business update. The conference call may be accessed by dialing 1-888-346-3959 (Domestic US) and 1-412-902-4262 (International), and asking to join the "Intrexon Corporation Call."  Participants may also access the live webcast through Intrexon's website in the Investors section under Calendar of Events. About Intrexon Corporation Intrexon Corporation (NYSE:XON) is Pow...
Oragenics Reports Positive In Vivo Antibiotic Efficacy Data in Critical Animal Study
Lead Lantibiotic Clinical Candidate Selected from MU1140 Analog Pipeline TAMPA, Fla. & GERMANTOWN, Md.--(BUSINESS WIRE)--Jul. 28, 2015-- Oragenics, Inc. (NYSE MKT: OGEN) and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, announced today positive data on multiple compounds from Oragenics’ Mutacin 1140 (“MU1140”) lantibiotic platform in a critical animal model study, as well as the selection of a lead clinical candidate. The compounds were subjected to a standardized “proof of concept” animal model evaluating efficacy for reducing clinically relevant C. difficile infection(s) and increased survival relative to vancomyc...
Intrexon Augments Management Team
- Jack Bobo named SVP, Chief Communications Officer - - Samuel Broder rejoins as SVP, Head of Health Sector - - Joel Liffmann appointed Senior Vice President, Finance - GERMANTOWN, Md., July 21, 2015 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced three additions to the executive team -- Jack A. Bobo, as Senior Vice President, Chief Communications Officer, Samuel Broder, M.D., as Senior Vice President, Head of Health Sector, and Joel Liffmann as Senior Vice President, Finance.  Mr. Bobo brings to Intrexon significant expertise in the analysis and communication of global trends in biotechnology, food and agriculture to audiences ...
Fibrocell and Intrexon Announce IND Filing of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Additional Positive Proof-of-Concept Data From in vivo Pre-Clinical Studies Highlighted EXTON, Pa. and GERMANTOWN, Md., July 20, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet needs, and Intrexon Corporation (NYSE:XON), a leader in synthetic biology, today announced the submission of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration for FCX-007, Fibrocell's lead orphan gene-therapy drug candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). R...
1